-
Je něco špatně v tomto záznamu ?
Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides
J. Zitko, B. Servusová, A. Janoutová, P. Paterová, J. Mandíková, V. Garaj, M. Vejsová, J. Marek, M. Doležal,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT13346
MZ0
CEP - Centrální evidence projektů
- MeSH
- amidy chemická syntéza chemie farmakologie MeSH
- antibakteriální látky chemická syntéza farmakologie MeSH
- antituberkulotika chemická syntéza farmakologie MeSH
- lidé MeSH
- pyrazinamid chemická syntéza chemie farmakologie MeSH
- tuberkulóza farmakoterapie MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Substitution of chlorine in 5-chloro-N-phenylpyrazine-2-carboxamide (1) with simple n-alkylamines yielded a series of 5-alkylamino-N-phenylpyrazine-2-carboxamides (propylamino to octylamino derivatives), which possessed similar or increased activity against Mycobacterium tuberculosis H37Rv compared to parent 5-chloro derivative (1), with MIC ranging from 2.5 to 12.2 μM. 5-Butylamino to 5-heptylamino derivatives exerted similar activity also against Mycobacterium kansasii. Importantly, the substitution led also to significant decrease of in vitro cytotoxicity in HepG2 cell line. 5-Heptylamino-N-phenylpyrazine-2-carboxamide (1e) exerted MIC=2.5 μM (M.tbc) and IC50 >250 μM (HepG2). Further modification of alkylamino chain with terminal methoxy or hydroxy group lead to compounds with decreased or none activity, the decrease was proportional to the decrease of lipophilicity. 5-(2-Phenylethylamino) and 5-(3-phenylpropylamino) derivatives were also of decreased activity. On contrary to alkylamino derivatives derived from 1, alkylamino derivatives derived from 5-chloro-N-2-chlorophenylpyrazine-2-carboxamide (2) possessed substantially decreased or none activity. None of the prepared compounds was active against Mycobacterium avium.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000517
- 003
- CZ-PrNML
- 005
- 20181212142804.0
- 007
- ta
- 008
- 160108s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bmc.2014.11.014 $2 doi
- 035 __
- $a (PubMed)25438883
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zitko, Jan. $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic. Electronic address: jan.zitko@faf.cuni.cz. $7 xx0230408
- 245 10
- $a Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides / $c J. Zitko, B. Servusová, A. Janoutová, P. Paterová, J. Mandíková, V. Garaj, M. Vejsová, J. Marek, M. Doležal,
- 520 9_
- $a Substitution of chlorine in 5-chloro-N-phenylpyrazine-2-carboxamide (1) with simple n-alkylamines yielded a series of 5-alkylamino-N-phenylpyrazine-2-carboxamides (propylamino to octylamino derivatives), which possessed similar or increased activity against Mycobacterium tuberculosis H37Rv compared to parent 5-chloro derivative (1), with MIC ranging from 2.5 to 12.2 μM. 5-Butylamino to 5-heptylamino derivatives exerted similar activity also against Mycobacterium kansasii. Importantly, the substitution led also to significant decrease of in vitro cytotoxicity in HepG2 cell line. 5-Heptylamino-N-phenylpyrazine-2-carboxamide (1e) exerted MIC=2.5 μM (M.tbc) and IC50 >250 μM (HepG2). Further modification of alkylamino chain with terminal methoxy or hydroxy group lead to compounds with decreased or none activity, the decrease was proportional to the decrease of lipophilicity. 5-(2-Phenylethylamino) and 5-(3-phenylpropylamino) derivatives were also of decreased activity. On contrary to alkylamino derivatives derived from 1, alkylamino derivatives derived from 5-chloro-N-2-chlorophenylpyrazine-2-carboxamide (2) possessed substantially decreased or none activity. None of the prepared compounds was active against Mycobacterium avium.
- 650 _2
- $a amidy $x chemická syntéza $x chemie $x farmakologie $7 D000577
- 650 _2
- $a antibakteriální látky $x chemická syntéza $x farmakologie $7 D000900
- 650 _2
- $a antituberkulotika $x chemická syntéza $x farmakologie $7 D000995
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pyrazinamid $x chemická syntéza $x chemie $x farmakologie $7 D011718
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a tuberkulóza $x farmakoterapie $7 D014376
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Servusová, Barbora $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic. $7 xx0230435
- 700 1_
- $a Janoutová, Alena $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
- 700 1_
- $a Paterová, Pavla $u Department of Clinical Microbiology, University Hospital, Sokolská 581, Hradec Králové 500 05, Czech Republic. $7 xx0138094
- 700 1_
- $a Mandíková, Jana $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic. $7 xx0159490
- 700 1_
- $a Garaj, Vladimír $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojárov 10, Bratislava 832 32, Slovakia. $7 _AN038040
- 700 1_
- $a Vejsová, Marcela $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic. $7 xx0106227
- 700 1_
- $a Marek, Jan $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
- 700 1_
- $a Doležal, Martin, $u Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic. $d 1961- $7 jn19981000714
- 773 0_
- $w MED00000769 $t Bioorganic & medicinal chemistry $x 1464-3391 $g Roč. 23, č. 1 (2015), s. 174-183
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25438883 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20181212142929 $b ABA008
- 999 __
- $a ok $b bmc $g 1102798 $s 924723
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 23 $c 1 $d 174-183 $e 20141115 $i 1464-3391 $m Bioorganic & medicinal chemistry $n Bioorg Med Chem $x MED00000769
- GRA __
- $a NT13346 $p MZ0
- LZP __
- $a Pubmed-20160108